Phase II Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy.
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 01 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Jan 2010 New trial record